Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gaucher Disease Registry Protocol

Trial Profile

Gaucher Disease Registry Protocol

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alglucerase (Primary) ; Eliglustat (Primary) ; Imiglucerase (Primary)
  • Indications Gaucher's disease; Gaucher's disease type I
  • Focus Therapeutic Use
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 15 Jun 2023 Results (n=381) assessing the hematologic and visceral response to eliglustat in patients enrolled in the ICGG GaucherRegistry across long-term follow-up presented at the 28th Congress of the European Haematology Association
    • 02 Feb 2022 Results (N=32), of a subgroup analysis assessing the baseline characteristics of patients with Gaucher disease who were treated with Imiglucerase in South African group, published in the South African Medical Journal
    • 15 Jul 2020 Protocol amended to include eliglustat drug and Gaucher Pregnancy Sub-registry in the trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top